EBD GmbH is part of the Knowledge & Networking Division of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
 
Biotech Showcase 2015 EBD Group Demy-Colton

Thank you for participating in Biotech Showcase™ 2016

Download your messages and statistics, bookmark and set notifications to track your leads, all on partnering360®.

The majority of Biotech Showcase™ 2016 delegates are already members of partnering360®.

partnering360: maximize your productivity by engaging and finding partners 24/7. Synchronize your in-person partnering with your online activity — all in one place.

See videos of Biotech Showcase ►
Tell us about your Biotech Showcase experience ►
Listen to Public company presentations ►

Save the date and check back in the coming weeks for information on next year's Biotech Showcase, January 9–11 in San Francisco, CA.

more ►

Conference videos

Interview: Armed with promising clinical data, Abivax seeks partners Interview: Armed with promising clinical data, Abivax seeks partnersJanuary 11, 2016 | Biotech Showcase™ 2015Abivax CEO details plans to develop and commercialize late-stage anti-HIV and hepatitis B compounds. View session here View session here
Interview: Nabriva plans second Phase III trial Interview: Nabriva plans second Phase III trial January 11, 2016 | Biotech Showcase™ 2015Nabriva Therapeutics plans to use IPO proceeds to complete two Phase III trials of lefamulin in CABP. View session here View session here
Interview: Abeona breaking into rare diseases Interview: Abeona breaking into rare diseasesJanuary 11, 2016 | Biotech Showcase™ 2015Abeona Therapeutics' President and CEO tells Mike Ward how his company is poised to enter the clinic with its lead gene therapy programs targeting some devastating lysosomal diseases. View session here View session here
Interview: C4 Therapeutics targets protein degradation Interview: C4 Therapeutics targets protein degradation January 12, 2016 | Biotech Showcase™ 2015C4 Therapeutics has developed a chemical strategy to target any disease-causing protein and then degrade it. Company executive chairman Marc Cohen explains how the approach works. View session here View session here
Interview: Canaan Partners outlines funding priorities Interview: Canaan Partners outlines funding prioritiesJanuary 12, 2016 | Biotech Showcase™ 2015Canaan Partners' Dr. Stephen Bloch outlines to Mike Ward the funding priorities of its 10th fund. View session here View session here
Interview: Corbus sees 2016 as pivotal year Interview: Corbus sees 2016 as pivotal yearJanuary 11, 2016 | Biotech Showcase™ 2015Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen tells Mike Ward, Informa Pharma Insights, that the next 12 months will be pivotal for the rare inflammatory disease company. View session here View session here
Interview: Grünenthal reveals plans to maintain robust growth in 2016 Interview: Grünenthal reveals plans to maintain robust growth in 2016January 11, 2016 | Biotech Showcase™ 2015Grünenthal’s CSO Klaus Langner discusses with Mike Ward of Informa Pharma Insights the company’s plans to expand beyond its core strength in pain management to niche therapeutic fields. View session here View session here
Interview: Faron Pharmaceuticals crosses Finnish line to increase global footprint Interview: Faron Pharmaceuticals crosses Finnish line to increase global footprintJanuary 11, 2016 | Biotech Showcase™ 2015Faron CEO Dr. Markku Jalkanen explains to Mike Ward, Informa Pharma Insights, how the company intends break out of Finland and build a larger global footprint. View session here View session here
Interview: Rigontec details imuuno-oncology strategy Interview: Rigontec details imuuno-oncology strategyJanuary 11, 2016 | Biotech Showcase™ 2015Rigontec CEO Dr. Christian Schetter tells Mike Ward how his company is tackling cancers and viral diseases with a novel RNA-based immuno-oncology strategy. View session here View session here
Fireside chat Fireside chatJanuary 13, 2016 | Biotech Showcase™ 2015An informal chat between Steve Dickman of CBT Advisors and Vijay Pande of Andreessen Horowitz from Digital Showcase 2016 covers the disruptive innovations of Digital Health. View session here View session here
At the intersection of technology and medicine At the intersection of technology and medicineJanuary 13, 2016 | Biotech Showcase™ 2015The convergence between technology and medicine is poised to have a profound effect on healthcare, impacting all of the stakeholders in the healthcare system View session here View session here
Advanced medical technology: What investors need to know Advanced medical technology: What investors need to knowJanuary 12, 2016 | Biotech Showcase™ 2015By reducing adverse side effects and identifying the right therapy for each patient, advanced drug delivery and diagnostics are key tools in improving the precision of advanced therapeutics. View session here View session here
Medtech Showcase State of the Industry Report Medtech Showcase State of the Industry ReportJanuary 12, 2016 | Biotech Showcase™ 2015Executives with deep experience in the device and diagnostic industry discuss the latest technologies with an eye to how they will help advance biopharmaceutical innovation. View session here View session here
The great pricing debate: Navigating through an industry sea change The great pricing debate: Navigating through an industry sea changeJanuary 11, 2016 | Biotech Showcase™ 2015Other national healthcare industries seem to have figured out how to shelve their self-interests, and evolve. We continue to be fragmented and self-interested. Where do we go from here? View session here View session here
The age of virtual pharma: Challenges and solutions for investor directors and successful boards The age of virtual pharma: Challenges and solutions for investor directors and successful boardsJanuary 11, 2016 | Biotech Showcase™ 2015The inability of pharma to absorb new assets through licensing and partnerships has not compromised future medicines development but has it inhibited further investment? View session here View session here
Bubble trouble? Have the biotech bulls had their run? Bubble trouble? Have the biotech bulls had their run?January 13, 2016 | Biotech Showcase™ 2015After posting its worst performance in 13 years in the third quarter, many are saying the biotech bull market has run its course. So what should investors expect for 2016? View session here View session here
State of the industry: It's different this time State of the industry: It's different this timeJanuary 12, 2016 | Biotech Showcase™ 2015The emergence of a cadre of profitable biotech companies is changing the traditional dynamic between big pharma, biotech and investors. How will the ecosystem continue to evolve? View session here View session here
Value creation: Private and Public investment strategies and stage gates for success
Value creation: Private and Public investment strategies and stage gates for success January 12, 2015 | Biotech Showcase™ 2015Senior life science industry executives discuss the key drivers that dictate value creation, and which pitfalls to avoid in acquisition, partnership or joint commercialization models. View session here View session here
Key trends in specialty drug management and their impact on product commercialization strategies
Key trends in specialty drug management and their impact on product commercialization strategies January 12, 2015 | Biotech Showcase™ 2015Manufacturers must demonstrate the clinical and economic value of specialty drugs like never before to align with the evolving business model and needs of health plans. View session here View session here
Are old funding models enough in a new era? Are old funding models enough in a new era?January 14, 2015 | Biotech Showcase™ 2015A healthy market for exits has replenished the pool of private capital for the biotech sector and new life sciences-oriented funds abound. How will all of this fresh capital be deployed? View session here View session here
Investing in the immuno-oncology revolution Investing in the immuno-oncology revolutionJanuary 14, 2015 | Biotech Showcase™ 2015The intersection of oncology and immunology will produce more headlines during 2015 as the next generation immunotherapies steadily progresses with extremely promising results. View session here View session here
Apps as drugs Apps as drugsJanuary 14, 2015 | Biotech Showcase™ 2015Startups are pushing forward in several disease areas to augment or supplant pharmaceutical approaches with online apps or computer programs. View session here View session here
How robust is the biotech rally and what could derail it? How robust is the biotech rally and what could derail it?January 13, 2015 | Biotech Showcase™ 2015The biotech rally has fueled a steady stream of IPOs over the last two years, and there is optimism that this time the market is driven by results rather than hype. View session here View session here
The Life Sciences Report 2015 Small-Cap Watchlist
The Life Sciences Report 2015 Small-Cap Watchlist January 13, 2015 | Biotech Showcase™ 2015Watch these biotech analysts articulate why their favorite small-cap ideas are good investment opportunities. Follow the progress of the "Watchlist" on The Life Sciences Report. View session here View session here
Type 1 Diabetes: Novel therapies, devices and diagnostics on the horizon
Type 1 Diabetes: Novel therapies, devices and diagnostics on the horizon January 13, 2015 | Biotech Showcase™ 2015This session highlights innovative therapies and devices in development to better treat, cure and prevent, reduce complications and relieve the daily burden of T1D. View session here View session here
Interview with Frederick Jones, Broadview Ventures Interview with Frederick Jones, Broadview VenturesJanuary 14, 2015 | Biotech Showcase™ 2015Broadview Ventures' Rick Jones discusses how they are taking a leadership position in venture philanthropy and making investments in promising ventures. View session here View session here
Interview with Christian Haller, RavenOye Group Interview with Christian Haller, RavenOye Group January 13, 2015 | Biotech Showcase™ 2015partneringNEWS interviewed Christian L. Haller, President of RavenOye Group, at Biotech Showcase 2015 to discuss the regulatory environment in Japan, and opportunities for partnering with Japanese medtech developers. View session here View session here
Interview with C. Randall Mills, CIRM Interview with C. Randall Mills, CIRM January 13, 2015 | Biotech Showcase™ 2015The new President and CEO of CIRM, C. Randal Mills, discusses new collaboration initiatives for national and international partners to help accelerate the development of advanced therapies for patients. View session here View session here
Regenerative Medicine and Advanced Therapies State of the Industry Briefing Regenerative Medicine and Advanced Therapies State of the Industry BriefingJanuary 12, 2015 | Biotech Showcase™ 2015Edward Lanphier, Chair of the Alliance for Regenerative Medicine, presents two panels comprising 13 expert speakers in advanced therapies in a State of the Industry Briefing. View session here View session here
Dose, delivery, data: Understanding the three D's of Advanced Therapy drug development
Dose, delivery, data: Understanding the three D's of Advanced Therapy drug development January 12, 2015 | Biotech Showcase™ 2015This panel of industry CEOs and senior executives in cell and gene therapies examines key issues related to advanced therapies as the field progresses over the next year. View session here View session here
Gene therapy and genome editing: Defining the clinical and commercial requirements for success
Gene therapy and genome editing: Defining the clinical and commercial requirements for success January 12, 2015 | Biotech Showcase™ 2015CEOs and senior executives from leading gene therapy companies look at the expected clinical, regulatory and commercial inflection points for the sector in 2015 and beyond. View session here View session here
Interview with Christian Haller Interview with Christian HallerJanuary 15, 2014 | Biotech Showcase™ 2014Christian L. Haller, President of RavenOye Group, discusses his company’s focus and services including strategic planning, and procuring access to experienced experts in marketing, regulation and payer groups. View session here View session here
Interview with Vicki Anastasi Interview with Vicki AnastasiJanuary 15, 2014 | Biotech Showcase™ 2014Vicki Anastasi, Senior VP of Aptiv Solutions, discusses hurdles facing the medtech sector and the future of financing medical devices. View session here View session here
Interview with Dalvir Gill, Transcelerate Interview with Dalvir Gill, TranscelerateJanuary 14, 2014 | Biotech Showcase™ 2014TransCelerate's CEO, Dalvir Gill, discusses the impact the organization has made in the clinical trial space, and the major milestones ahead that will help to create a more successful drug development process. View session here View session here
Interview with Dennis Purcell Interview with Dennis PurcellJanuary 14, 2014 | Biotech Showcase™ 2014Wall Street has finally caught up to science, making 2013 a very good year for investment. Dennis Purcell of Aisling Capital outlines the new investment landscape, and why the outlook for biotech investing is promising. View session here View session here
Interview with Alex Zisson, Thomas, McNerney Interview with Alex Zisson, Thomas, McNerneyJanuary 13, 2014 | Biotech Showcase™ 2014With respect to previous years of biotech investment, 2013 was a year to savor. Alex Zisson of Thomas, McNerney describes the conditions that threw open the IPO window, and what looming risks could force it to slam shut. View session here View session here
Sources of alternative funding in difficult times Sources of alternative funding in difficult timesJanuary 15, 2014 | Biotech Showcase™ 2014Panelists discuss the current investment environment for start-ups and the latest strategies when seeking funding, including alternative funding sources for emerging companies. View session here View session here
Life sciences investment and financing climate in Europe Life sciences investment and financing climate in EuropeJanuary 15, 2014 | Biotech Showcase™ 2014VC financing is far behind in Europe vs. the US. However, Europe still has a strong biotech Industry. Key investors discuss where financing in Europe is coming from. View session here View session here
The changing dynamic of the drug development ecosystem The changing dynamic of the drug development ecosystem January 14, 2014 | Biotech Showcase™ 2014Traditionally, drug development programs haven't focused on the needs of patients or payers. Now, patients, payers and investors are seeking more of a voice in drug development decisions. View session here View session here
Parkinson’s disease:  On the threshold of new therapies in an area of high unmet need Parkinson’s disease: On the threshold of new therapies in an area of high unmet needJanuary 14, 2014 | Biotech Showcase™ 2014Investigators are on the cusp of discovery and drug development that will improve current symptomatic treatments, allow for earlier diagnosis, and provide the cure for Parkinson’s. View session here View session here
New models in biotechnology: Innovative structures, financing options and risk sharing opportunities New models in biotechnology: Innovative structures, financing options and risk sharing opportunitiesJanuary 13, 2014 | Biotech Showcase™ 2014Now that the IPO markets have returned and some VC firms have replenished their coffers to fund small and mid-stage companies, what role will alternatives play going forward? View session here View session here
Alliance for Regenerative Medicine: State of the Industry Briefing Alliance for Regenerative Medicine: State of the Industry BriefingJanuary 13, 2014 | Biotech Showcase™ 2014Alliance for Regenerative Medicine’s State of the Industry Briefing is a top-level gathering for key stakeholders in this sector, providing an overview of the sector's outlook. View session here View session here
Biotech Showcase, Streetwise Reports and Sagient Research Present The Life Sciences Report Watchlist 2014 Biotech Showcase, Streetwise Reports and Sagient Research Present The Life Sciences Report Watchlist 2014January 13, 2014 | Biotech Showcase™ 2014Learn which companies made the 2014 Watchlist based on major catalysts according to analysts at Sagient Research and in-depth company analysis from industry experts. View session here View session here
Big Data in drug discovery Big Data in drug discoveryJanuary 14, 2014 | Biotech Showcase™ 2014Unlike most markets already tackled by Big Data, life sciences markets are heavily regulated and traditional methods are deeply entrenched. Still, Big Data is making inroads. View session here View session here
Interview with Steve Yang, AstraZeneca and May Wang, Hutchison MediPharma Interview with Steve Yang, AstraZeneca and May Wang, Hutchison MediPharmaJanuary 7, 2013 | Biotech Showcase™ 2013Steve Yang of AstraZeneca and May Wang of Hutchison MediPharma discuss their recent deal, and how it is emblematic of AstraZeneca's partnering-fueled growth strategy in China. View session here View session here
Interview with Lauren Barnes, Avalere Health and Josh Bilenker, Aisling Capital Interview with Lauren Barnes, Avalere Health and Josh Bilenker, Aisling CapitalJanuary 7, 2013 | Biotech Showcase™ 2013Are payers the new boogeyman for biotechs? Pricing and reimbursement specialist Lauren Barnes and investor Josh Bilenker discuss what payers' increasing influence means for the industry. View session here View session here
Interview with Dennis Purcell, Aisling Capital Interview with Dennis Purcell, Aisling CapitalJanuary 8, 2013 | Biotech Showcase™ 2013Sara Jane Demy interviews Dennis Purcell about investor outlook on issues from IPOs to therapeutic areas, and the role of Biotech Showcase™ in transforming biotech investing. View session here View session here
The Watch List of 2013 The Watch List of 2013January 7, 2013 | Biotech Showcase™ 2013Learn what top biotech analysts think are the driving macro trends and specific opportunities for 2013, including exciting new therapy areas, and how investors can capitalize on them. View session here View session here
2013 Regenerative Medicine State of the Industry Briefing 2013 Regenerative Medicine State of the Industry BriefingJanuary 8, 2013 | Biotech Showcase™ 2013Alliance for Regenerative Medicine’s State of the Industry Briefing discusses recent advances in major disease areas and the outlook for regenerative medicine and cell therapy. View session here View session here
Regenerative Medicine Analyst Outlook 2013 Regenerative Medicine Analyst Outlook 2013January 8, 2013 | Biotech Showcase™ 2013This panel of expert healthcare buy side and sell side analysts focusing on regenerative medicine discuss the outlook for the sector from the investor's perspective. View session here View session here
How asset-centric biotech structures can open new avenues for achieving liquidity How asset-centric biotech structures can open new avenues for achieving liquidityJanuary 7, 2013 | Biotech Showcase™ 2013As the IPO and M&A path to liquidity for investors in the typical company-centric models gets tougher, alternate structures focusing on assets are proving attractive. View session here View session here
The view from the street:  Looking forward The view from the street: Looking forwardJanuary 9, 2013 | Biotech Showcase™ 2013This panel of seasoned biotech investors and analysts has a candid and open discussion on what to expect in biotech funding and business development in 2013/14. View session here View session here
Open innovation: Driver of future healthcare solutions? Open innovation: Driver of future healthcare solutions?January 9, 2013 | Biotech Showcase™ 2013Hear about the latest developments in healthcare open innovation activities, how to meet challenges and establish projects, as well as the role of crowdfunding. View session here View session here
Obesity:  A big problem. Where are we today and where are we going?  Obesity: A big problem. Where are we today and where are we going? January 9, 2013 | Biotech Showcase™ 2013Development of drugs, devices and procedures for the treatment of obesity has been complex and difficult, especially navigating through safety, efficacy and regulatory concerns. View session here View session here
Funding biotech: Do we need a superfund? Funding biotech: Do we need a superfund?January 8, 2013 | Biotech Showcase™ 2013Mark Kessel contends that a superfund is a viable tool that can address the need to fund innovation for both biotech and pharma. View session here View session here
eHealth: Medicine’s next frontier eHealth: Medicine’s next frontier January 8, 2013 | Biotech Showcase™ 2013eHealth represents a new way of treating patients that could have a major impact on stakeholders in the healthcare system including doctors, patients and the pharma industry. View session here View session here
Interview with Shaun Grady, AstraZeneca Interview with Shaun Grady, AstraZenecaJanuary 7, 2013 | Biotech Showcase™ 2013Shaun Grady of AstraZeneca discusses the high cadence of partnering deals in 2012, and the firm's strategy to become the partner of choice in the industry. View session here View session here
Deciding to go commercial in the go-it-alone era: Can we resolve the risk vs. the reward? Deciding to go commercial in the go-it-alone era: Can we resolve the risk vs. the reward?January 7, 2013 | Biotech Showcase™ 2013This panel of senior executives from emerging biotechs, large pharma, VC firms and investment banks discusses the risks and rewards of pursuing an independent commercialization strategy. View session here View session here
Life sciences innovation: The struggle to retain and attract investors Life sciences innovation: The struggle to retain and attract investorsJanuary 11, 2012 | Biotech Showcase™ 2012Many VCs are eliminating investments in US life science companies or shifting focus because of perceived regulatory obstacles. How can companies address these obstacles? View session here View session here
Molecular diagnostics: A sector of increasing importance Molecular diagnostics: A sector of increasing importanceJanuary 11, 2012 | Biotech Showcase™ 2012Experienced MDx developers, investors, dealmakers and policy advocates explore the challenges and opportunities within the MDx sector, including partnering your product. View session here View session here
Getting a drug approved as the FDA Is evolving Getting a drug approved as the FDA Is evolvingJanuary 11, 2012 | Biotech Showcase™ 2012Despite the FDA’s new Innovation Initiative, there is still the need for companies with drugs in advanced stages of development to have a strategy to get them approved. View session here View session here
Shifting sands: What will drive the next phase of value for the pharma and biotech industries? Shifting sands: What will drive the next phase of value for the pharma and biotech industries?January 10, 2012 | Biotech Showcase™ 2012The interests of large pharma have shifted from filling late stage pipeline gaps to deals in early stage assets. How will this affect the partnering strategies of biotechs? View session here View session here
Case study of the AstraZeneca/Rigel partnership Case study of the AstraZeneca/Rigel partnershipJanuary 10, 2012 | Biotech Showcase™ 2012Dealmakers discuss the partnership between AstraZeneca and Rigel View session here View session here
Alternative financing options for life science companies Alternative financing options for life science companiesJanuary 10, 2012 | Biotech Showcase™ 2012This workshop focuses on what tools an emerging company can use to finance their development programs, including a discussion on debt, royalty and government backed options. View session here View session here
The 2nd annual Regenerative Medicine State of the Industry briefing The 2nd annual Regenerative Medicine State of the Industry briefingJanuary 10, 2012 | Biotech Showcase™ 2012The Alliance for Regenerative Medicine presents a briefing on the state of the cell therapy and regenerative medicine industries, including major clinical developments. View session here View session here
Reimbursement: A critical component of valuation Reimbursement: A critical component of valuationJanuary 9, 2012 | Biotech Showcase™ 2012Panelists discuss high level strategies for obtaining coverage and maximizing payment amounts for products in today’s environment and under evolving CMS standards. View session here View session here
Redefining exit options given the current economic climate Redefining exit options given the current economic climateJanuary 9, 2012 | Biotech Showcase™ 2012Panelists discuss liquidity options for their portfolio companies, risk reduction deal structures they are proposing, and funding options being adopted by management. View session here View session here
Infectious disease: Fighting the #2 global killer Infectious disease: Fighting the #2 global killerJanuary 9, 2012 | Biotech Showcase™ 2012According to the WHO, almost a quarter of deaths globally are due to infectious diseases, but there are promising new approaches in the war against these killers. View session here View session here

Share/Follow Us
Share this:
Follow this event:

Biotech Showcase™ 2016

Biotech Showcase™ 2016 Highlights

  • 336 company presentations
  • 2,545 attendees
  • 1,605 companies
  • 44 countries represented
  • 5,650 one-to-one meetings
  • 21 workshops and panels

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.

Now in its eighth year, Biotech Showcase 2016 is expected to attract upwards of 2,100 attendees. The program includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry- and time-relevant topics, as well as presentations from both private and public companies.
more about this conference ►

Did you miss the free webinar on how to maximize your JPM/Biotech Showcase week? Listen to it here. ►

New Programs in 2016

The three-day program features multiple tracks of presenting companies, plenary sessions, the opportunity to schedule one-to-one meetings and networking. 2016 offers two new, one-day tracks dedicated to connecting innovative medtech and digital health companies with investors:

* Medtech Showcase: January 12   * Digital Health Showcase: January 13


more ►

#BTS16 on Twitter



Arrow Up

Follow this event:
Sign up now
For news and updates

Privacy Policy and Cookies Terms of Use

Home | Contact Us | Site Map
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2016 EBD Group, Inc.
Privacy Policy and Cookies
Terms of Use